As shown in a recent clinical trial, CAR-T therapy targeting CD5 is an attractive strategy in patients with r/r CD5+ T cell malignancies without resulting in a life-threatening immunodeficiency.9 This evidence concerns the gene CD5 and Immunodeficiency.